General Information of Drug (ID: DM54M6C)

Drug Name
2-(2-(2,5-dichlorophenylamino)phenyl)acetic acid Drug Info
Synonyms
CHEMBL77981; 2-(2-(2,5-dichlorophenylamino)phenyl)acetic acid; SCHEMBL7166052; JSJQNYIFLKCXRE-UHFFFAOYSA-N; ZINC13809288; BDBM50090679; 2-(2,5-Dichloroanilino)benzeneacetic acid; 2-[(2,5-dichlorophenyl)amino]phenylacetic acid; [2-(2,5-Dichloro-phenylamino)-phenyl]-acetic acid
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
14076674
TTD Drug ID
DM54M6C

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug(s) Targeting Interleukin-8 (IL8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [1]
ABX-IL8 DMCZFMS Melanoma 2C30 Phase 2 [2]
BMS-986253 DM42B0C Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [3]
MDX-018 DML5FX2 Autoimmune diabetes 5A10 Phase 1 [4]
R-ketoprofen DMHSUQ1 N. A. N. A. Discontinued in Phase 2 [1]
2-(2-(2-chlorophenylamino)phenyl)acetic acid DMPLV3A Discovery agent N.A. Investigative [1]
2-(2-(2-fluorophenylamino)phenyl)acetic acid DMVQ68F Discovery agent N.A. Investigative [1]
2-(2-(2-chlorophenoxy)phenyl)acetic acid DMBP1TQ Discovery agent N.A. Investigative [1]
2-(2-(2-fluorophenoxy)phenyl)acetic acid DMDSUR2 Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-8 (IL8) TTCTE1G IL8_HUMAN Inhibitor [1]

References

1 Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30.
2 Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol. 2002 Jul;161(1):125-34.
3 Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. J Immunother Cancer. 2019 Sep 5;7(1):240.
4 Company report (Genmab)